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Autoimmune lymphoproliferative syndrome (ALPS) is characterized by lymphoproliferative disease, autoimmune 
cytopenias and increased susceptibility to lymphoid malignancies. Central to the pathophysiology of the disease are 
defects in the FAS signaling leading to impaired lymphocyte homeostasis. Most of the patients harbor 
heterozygous germline or somatic mutations in FAS. The hallmark of the disease is the impaired FAS-mediated 
apoptosis of activated T cells and presence of atypical "double-negative" T cells 
(CD3+TCRalpha/beta+CD4-CD8-). While FAS is essential for deletion of autoreactive B cells in the germinal 
center in murine models, the role of FAS in human B cell selection and development of autoimmunity in patients 
carrying FAS mutation is unclear. 
We analyzed patients with somatic FAS mutation or germline FAS mutation plus somatic loss-of-heterozygosity 
allowing to compare the fate of B cells with impaired versus normal FAS signaling within the same individual. We 
found in the class-switched memory B cells: 1) accumulation of FAS- mutated B cells, 2) a failure to enrich single 
V genes and in single V-D, D-J gene combinations of the B cell receptor variable region, 3) increased frequency of 
variable regions with higher content of positively charged amino acids and longer CDR3 and 4) maintenance of 
polyreactive specificities. Importantly, FAS-deficient switched memory B cells showed increased rates of somatic 
hypermutation. Our data uncover a defect in B cell selection in ALPS patients and indicate a role for B cell 
dysregulation in the pathogenesis of autoimmunity and B-cell lymphoma in ALPS patients. 
